Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4 USD | +0.03% | 0.00% | -39.78% |
Business Summary
Number of employees: 18
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Therapeutics
100.0
%
| 1 | 100.0 % | 0 | 100.0 % | -64.72% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 1 | 100.0 % | 0 | 100.0 % | -64.72% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Peter Altman
CEO | Chief Executive Officer | 57 | 01-12-31 |
David McClung
DFI | Director of Finance/CFO | 61 | 13-08-31 |
Chief Tech/Sci/R&D Officer | - | 17-07-31 | |
Sujith Shetty
CTO | Chief Tech/Sci/R&D Officer | - | 19-02-28 |
Ian McNiece
CTO | Chief Tech/Sci/R&D Officer | 70 | 17-11-07 |
Anne Laluc
IRO | Public Communications Contact | - | - |
Mark Schwartz
PRN | Corporate Officer/Principal | - | 18-10-31 |
Edward Gillis
PRN | Corporate Officer/Principal | 62 | 19-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Simon Stertzer
BRD | Director/Board Member | 88 | 01-12-31 |
Jay Moyes
BRD | Director/Board Member | 70 | 10-12-31 |
Richard Krasno
BRD | Director/Board Member | 82 | 16-10-23 |
Director/Board Member | 53 | 23-10-17 | |
Peter Altman
CEO | Chief Executive Officer | 57 | 01-12-31 |
Andrew Blank
CHM | Chairman | 68 | 19-09-30 |
Jim Allen
BRD | Director/Board Member | 69 | 19-09-30 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 27,304,116 | 18,818,749 ( 68.92 %) | 0 | 68.92 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-39.78% | 10.74M | |
+7.81% | 113B | |
+10.90% | 106B | |
+0.41% | 22.27B | |
-11.89% | 22.22B | |
-5.99% | 19.43B | |
-37.36% | 17.87B | |
-5.63% | 17.24B | |
+6.76% | 14.29B | |
+35.78% | 12.52B |
- Stock Market
- Equities
- BCDA Stock
- Company BioCardia, Inc.